From the Department of Internal Medicine (R.A.M.), Department of Community Health Sciences (R.A.M., A.M.), and Manitoba Centre for Health Policy (A.M., O.E.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba; ICES (C. Maxwell), Toronto; Schools of Pharmacy and Public Health & Health Systems (C. Maxwell), University of Waterloo; ICES Queen's (A.M., C. McClintock, D.S., P.A.G.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Departments of Psychiatry and Community Health Sciences (D.S.), Cumming School of Medicine, University of Calgary; Ottawa Hospital Research Institute (C.W.); and Bruyère Research Institute (C.W.), Ottawa, Canada.
Neurology. 2021 Jan 26;96(4):e501-e512. doi: 10.1212/WNL.0000000000011219. Epub 2020 Nov 25.
To determine whether cancer risk differs in people with and without multiple sclerosis (MS), we compared incidence rates and cancer-specific mortality rates in MS and matched cohorts using population-based data sources.
We conducted a retrospective matched cohort study using population-based administrative data from Manitoba and Ontario, Canada. We applied a validated case definition to identify MS cases, then selected 5 controls without MS matched on birth year, sex, and region. We linked these cohorts to cancer registries, and estimated incidence of breast, colorectal, and 13 other cancers. For breast and colorectal cancers, we constructed Cox models adjusting for age at the index date, area-level socioeconomic status, region, birth cohort year, and comorbidity. We pooled findings across provinces using meta-analysis.
We included 53,983 MS cases and 269,915 controls. Multivariable analyses showed no difference in breast cancer risk (pooled hazard ratio [HR] 0.92 [95% confidence interval (CI) 0.78-1.09]) or colorectal cancer risk (pooled HR 0.83 [95% CI 0.64-1.07]) between the cohorts. Mortality rates for breast and colorectal did not differ between cohorts. Bladder cancer incidence and mortality rates were higher among the MS cohort. Although the incidence of prostate, uterine, and CNS cancers differed between the MS and matched cohorts, mortality rates did not.
The incidence of breast and colorectal cancers does not differ between persons with and without MS; however, the incidence of bladder cancer is increased. Reported differences in the incidence of some cancers in the MS population may reflect ascertainment differences rather than true differences.
为了确定多发性硬化症(MS)患者和非 MS 患者的癌症风险是否存在差异,我们使用基于人群的数据源比较了 MS 和匹配队列的发病率和癌症特异性死亡率。
我们使用来自加拿大马尼托巴省和安大略省的基于人群的行政数据进行了回顾性匹配队列研究。我们应用了经过验证的病例定义来识别 MS 病例,然后选择了 5 名没有 MS 的对照者,他们在出生年份、性别和地区上与 MS 患者相匹配。我们将这些队列与癌症登记处进行了关联,并估计了乳腺癌、结直肠癌和其他 13 种癌症的发病率。对于乳腺癌和结直肠癌,我们构建了 Cox 模型,以调整索引日期时的年龄、地区级社会经济地位、地区、出生队列年份和合并症。我们使用荟萃分析汇总了各省的研究结果。
我们纳入了 53983 例 MS 病例和 269915 名对照者。多变量分析显示,两组之间的乳腺癌风险(汇总危险比 [HR] 0.92 [95%置信区间(CI)0.78-1.09])或结直肠癌风险(汇总 HR 0.83 [95% CI 0.64-1.07])没有差异。两组之间的乳腺癌和结直肠癌死亡率没有差异。膀胱癌的发病率和死亡率在 MS 队列中较高。尽管 MS 队列和匹配队列之间的前列腺癌、子宫癌和中枢神经系统癌症的发病率存在差异,但死亡率没有差异。
MS 患者和非 MS 患者的乳腺癌和结直肠癌发病率没有差异;然而,膀胱癌的发病率增加。在 MS 人群中报告的某些癌症发病率的差异可能反映了检出差异而不是真正的差异。